Print  |  Close

A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia


Active: No
Cancer Type: Leukemia NCT ID: NCT01303796
Trial Phases: Phase III Protocol IDs: CYC682-12 (primary)
Eligibility: 70 and over, Male and Female Study Type: Treatment
Study Sponsor: Cyclacel Pharmaceuticals, Incorporated
NCI Full Details: http://clinicaltrials.gov/show/NCT01303796

Summary

This Phase 3 study assesses three drug regimens as the initial treatment of patients who are at least 70 years of age and have newly diagnosed acute myeloid leukemia (AML) for whom the doctor does not recommend the use of standard intensive treatment or the patient has decided not to receive standard intensive treatment after being fully informed about its benefits and risks by his/her doctor. The three drug regimens are sapacitabine administered in alternating cycles with decitabine, sapacitabine alone or decitabine alone. The purpose of the study is to learn which drug regimen is more likely to keep AML in check as long as possible.

Objectives

This is a multicenter, randomized, Phase 3 study comparing three drug regimens (arms) as the front-line treatment of elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy. In Arm A, sapacitabine is administered in alternating cycles with decitabine, in Arm B sapacitabine is administered alone and in Arm C decitabine is administered alone. The primary efficacy endpoint is overall survival. The study is designed to demonstrate an improvement in overall survival of either of two pairwise comparisons: (1) Arm A versus Arm C or (2) Arm B versus Arm C.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.